NASDAQ: INBXV - Inhibrx, Inc.

Rentabilidade por seis meses: 0%
Rendimento de dividendos: 0.00%
Setor: Нефтегаз

Cronograma de promoção Inhibrx, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

mais detalhes
It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2024-05-28
Валюта usd
Сайт https://inhibrx.com
Цена ао 30.85
Alteração de preço por dia: 0% (30.85)
Alteração de preço por semana: 0% (30.85)
Alteração de preço por mês: 0% (30.85)
Alteração de preço em 3 meses: 0% (30.85)
Mudança de preço em seis meses: 0% (30.85)
Mudança de preço desde o início do ano: 0% (30.85)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Eficiência

Nome Significado Nota
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA 0 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 0 0
Rentabilidade Ebitda, % 0 0
Rentabilidade EPS, % 0 0
Total: 0
Mais detalhes



Supervisor Cargo Pagamento Ano de nascimento
Mr. Mark Paul Lappe Founder, Chairman, President & CEO 1967 (58 anos)
Dr. Brendan P. Eckelman Ph.D. Founder & Chief Scientific Officer 1979 (46 anos)
Mr. Quinn L. Deveraux Founder
Dr. Ashraf Amanullah Executive VP & Chief Technical Operations Officer 1968 (57 anos)
Ms. Leah Pollema J.D. VP, Corporate Secretary & General Counsel
Dr. Charbel Helaihel Pharm.D. Vice President of Marketing & Commercial Planning
Mr. Jeffrey J. Jensen Executive VP & Chief Clinical Operations Officer
Mr. David Matly M.B.A. Executive VP and Chief Commercial & Business Development Officer
Dr. Carlos Bais Ph.D. Executive Vice President of Translational Sciences
Dr. Josep Garcia Ph.D. EVP & Chief Clinical Development Officer

Endereço: United States, La Jolla, 11025 North Torrey Pines Road - abrir no Google Maps, abrir mapas Yandex
Site: https://inhibrx.com